摘要
以N-甲基-4-氯-2-吡啶甲酰胺为原料,经过4步共合成4个化合物(S-1,S-2,R-1和R-2),其中2个为新的化合物(S-1和R-2)。经过1H NMR,13C NMR,HR-MS等方法对其结构表征。最后通过CTG法,测试4种化合物对四种人肝癌细胞(PLC/PRF/5,Hep3B,HepG2,BEL-7402)的抑制活性。结果表明:S-1,S-2,R-1和R-2均表现较明显的对4种细胞的抑制活性,且呈现出浓度依赖关系。IC50值从1304nM到11228nM。其中化合物R-1(瑞格非尼)对PLC/PRF/5和HepG2细胞,S-1对Hep3B细胞的抑制活性,R-2对HepG2的细胞活性均较高于原药索拉非尼。
Four compounds(S-1,S-2,R-1 and R-2)including two novel compounds(S-1 and R-2)were synthesized via a four-step procedure starting from N-methyl-4-chloropyridine-2-carboxamide.Their structures were confirmed by 1H NMR,13C NMR and HR-MS.Their antitumor activities against various human hepatoma carcinoma cell lines(PLC/PRF/5,Hep3B,HepG2 and BEL-7402)in vivo were evaluated by CTG arrays.The antitumor screening assay showed that compound S-1,S-2,R-1 and R-2 exhibited obvious antitumor activities with IC50 range from 1304nM to 11228nM in concentration-dependent manner.Compound R-1(Regorafenib)(against tumor cell line PLC/PRF/5 and HepG2),compound S-1(against tumor cell line Hep3B),compound R-2(against tumor cell line HepG2)exhibited slightly better antitumor activity than Sorafenib.
作者
李伟林
郑学良
梁青
马耀
LI Wei-ling;ZHENG Xue-liang;LIANG Qing;MA Yao(Shanxi Chemical Research Institute(Co.,Ltd),Taiyuan 030021,China)
出处
《化学研究与应用》
CAS
CSCD
北大核心
2020年第1期134-138,共5页
Chemical Research and Application
基金
山西省青年科技研究基金项目(201701D221150)资助
关键词
氟代
合成
抗肿瘤活性
fluorination
synthesis
antitumor activity